solifenacin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
muscarinic receptors antagonists 2457 242478-37-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • YM-67905
  • YM-905
  • solifenacin
  • solifenacin succinate
  • vesicare
A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.
  • Molecular weight: 362.47
  • Formula: C23H26N2O2
  • CLOGP: 4.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 32.78
  • ALOGS: -3.70
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 12.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 8.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 52 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 2004 FDA ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dry mouth 197.77 11.35 179 22505 55999 50526441
Multiple sclerosis relapse 126.43 11.35 124 22560 42840 50539600
Urinary retention 111.36 11.35 93 22591 26097 50556343
Fall 105.96 11.35 360 22324 334572 50247868
Urinary incontinence 71.25 11.35 75 22609 28133 50554307
Urinary tract infection 67.35 11.35 237 22447 223783 50358657
Vision blurred 64.88 11.35 122 22562 78525 50503915
Residual urine volume increased 62.43 11.35 11 22673 20 50582420
Gait disturbance 57.03 11.35 172 22512 149833 50432607
Multiple sclerosis 52.66 11.35 55 22629 20438 50562002
Fear of eating 49.44 11.35 14 22670 326 50582114
Dementia 48.57 11.35 47 22637 15950 50566490
Maternal exposure during pregnancy 48.44 11.35 7 22677 159771 50422669
Arteriovenous fistula occlusion 47.94 11.35 14 22670 365 50582075
Blue toe syndrome 46.99 11.35 14 22670 392 50582048
Constipation 45.41 11.35 184 22500 185524 50396916
Drug intolerance 40.52 11.35 24 22660 219080 50363360
Contraindicated product administered 37.86 11.35 10 22674 148948 50433492
Hallucination 36.75 11.35 71 22613 46586 50535854
Synovitis 36.23 11.35 6 22678 123859 50458581
Lymphocyte count decreased 35.51 11.35 51 22633 26256 50556184
Hand deformity 33.84 11.35 3 22681 100196 50482244
Cerebellar syndrome 33.51 11.35 20 22664 3291 50579149
Cutaneous T-cell dyscrasia 30.89 11.35 7 22677 63 50582377
Cutaneous lupus erythematosus 30.80 11.35 17 22667 2414 50580026
Infusion related reaction 30.74 11.35 19 22665 169538 50412902
Renal pain 30.40 11.35 23 22661 5596 50576844
Treatment failure 30.10 11.35 12 22672 137625 50444815
Bladder sphincter atony 29.55 11.35 8 22676 157 50582283
Balance disorder 28.74 11.35 83 22601 70507 50511933
Dry throat 28.33 11.35 22 22662 5562 50576878
Nodular rash 27.83 11.35 8 22676 197 50582243
Confusional state 27.17 11.35 159 22525 185769 50396671
Toxicity to various agents 26.31 11.35 34 22650 212465 50369975
Discomfort 26.19 11.35 8 22676 108372 50474068
Exposure during pregnancy 25.74 11.35 11 22673 121004 50461436
Glossodynia 25.39 11.35 10 22674 115559 50466881
Sinus arrest 24.66 11.35 13 22671 1685 50580755
Bladder disorder 24.49 11.35 23 22661 7520 50574920
Dysuria 24.46 11.35 45 22639 28459 50553981
Disorientation 24.36 11.35 51 22633 35433 50547007
Swelling 23.99 11.35 33 22651 200839 50381601
Therapeutic product effect decreased 23.62 11.35 16 22668 136034 50446406
Sinus node dysfunction 23.21 11.35 17 22667 3938 50578502
Cystitis 22.77 11.35 57 22627 44507 50537933
Poliomyelitis 21.87 11.35 5 22679 47 50582393
Pyelonephritis 21.62 11.35 30 22654 14959 50567481
Rheumatoid arthritis 21.56 11.35 36 22648 202514 50379926
Dyskinesia 21.45 11.35 42 22642 27819 50554621
Joint swelling 21.43 11.35 49 22635 245237 50337203
Dyspepsia 21 11.35 77 22607 74020 50508420
Renal function test abnormal 20.80 11.35 14 22670 2835 50579605
Hallucination, visual 20.72 11.35 31 22653 16551 50565889
Pericarditis 20.53 11.35 5 22679 78684 50503756
Hypertonic bladder 20.15 11.35 14 22670 2986 50579454
Muscular weakness 19.98 11.35 90 22594 94923 50487517
Malaise 19.10 11.35 232 22452 335300 50247140
Heat stroke 18.88 11.35 8 22676 635 50581805
Micturition urgency 17.44 11.35 20 22664 8244 50574196
Dizziness 17.39 11.35 234 22450 346135 50236305
Hyponatraemia 17.26 11.35 87 22597 96052 50486388
Lower urinary tract symptoms 17.09 11.35 4 22680 42 50582398
Oscillopsia 16.99 11.35 5 22679 134 50582306
Pain 16.93 11.35 172 22512 578731 50003709
Colitis ischaemic 16.80 11.35 21 22663 9462 50572978
Off label use 16.40 11.35 301 22383 474125 50108315
Neurogenic bladder 16.13 11.35 12 22672 2845 50579595
Torsade de pointes 16.05 11.35 23 22661 11812 50570628
Thalamus haemorrhage 15.97 11.35 7 22677 603 50581837
Hepatic enzyme increased 15.96 11.35 23 22661 137357 50445083
Incontinence 15.94 11.35 21 22663 9964 50572476
Upper gastrointestinal haemorrhage 15.93 11.35 27 22657 16008 50566432
Lower respiratory tract infection 15.47 11.35 12 22672 95189 50487251
Dry eye 15.30 11.35 40 22644 32055 50550385
Drug abuse 15.23 11.35 4 22680 59842 50522598
Wound 15.18 11.35 15 22669 105779 50476661
Labelled drug-drug interaction medication error 15.16 11.35 21 22663 10456 50571984
Benign renal neoplasm 14.76 11.35 3 22681 15 50582425
Visual impairment 14.59 11.35 65 22619 68210 50514230
Blood viscosity increased 14.45 11.35 5 22679 228 50582212
Arthropathy 14.22 11.35 31 22653 157875 50424565
Varicose ulceration 13.81 11.35 6 22678 506 50581934
Vasculitic rash 13.80 11.35 8 22676 1247 50581193
Pollakiuria 13.78 11.35 32 22652 23819 50558621
Memory impairment 13.67 11.35 71 22613 79289 50503151
Language disorder 13.57 11.35 9 22675 1779 50580661
Atrial fibrillation 13.56 11.35 85 22599 101660 50480780
Wrong technique in product usage process 13.53 11.35 55 22629 55455 50526985
Cognitive disorder 13.48 11.35 47 22637 44076 50538364
Abdominal discomfort 13.31 11.35 56 22628 231585 50350855
Subacute hepatic failure 13.10 11.35 4 22680 122 50582318
Poverty of speech 12.89 11.35 5 22679 316 50582124
Cerebral haematoma 12.81 11.35 11 22673 3200 50579240
Escherichia urinary tract infection 12.37 11.35 19 22665 10376 50572064
Posture abnormal 12.30 11.35 9 22675 2080 50580360
Hereditary angioedema with C1 esterase inhibitor deficiency 12.23 11.35 3 22681 39 50582401
Inappropriate schedule of product administration 12.19 11.35 64 22620 71767 50510673
Nodal rhythm 12.07 11.35 8 22676 1579 50580861
JC polyomavirus test positive 12.01 11.35 7 22677 1102 50581338
Hyperthermia 12.00 11.35 16 22668 7680 50574760
Lip swelling 11.97 11.35 31 22653 24705 50557735
Delirium 11.94 11.35 41 22643 38151 50544289
Urge incontinence 11.92 11.35 6 22678 707 50581733
Acute kidney injury 11.80 11.35 155 22529 227903 50354537
Febrile neutropenia 11.69 11.35 16 22668 97651 50484789
Airway remodelling 11.48 11.35 3 22681 51 50582389
Muscle strain 11.46 11.35 15 22669 7073 50575367

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dry mouth 94.18 15.01 69 9731 21715 29543012
Urinary retention 90.71 15.01 79 9721 31819 29532908
Confusional state 78.79 15.01 147 9653 127730 29436997
Hallucination 63.27 15.01 76 9724 44636 29520091
Constipation 56.71 15.01 120 9680 114040 29450687
Fall 52.71 15.01 153 9647 177025 29387702
Urinary incontinence 31.86 15.01 33 9767 16448 29548279
Duplicate therapy error 29.41 15.01 7 9793 110 29564617
Urosepsis 29.28 15.01 26 9774 10720 29554007
Urinary tract infection 29.09 15.01 70 9730 72284 29492443
Gastrointestinal hypomotility 29.07 15.01 11 9789 882 29563845
Hallucination, visual 28.91 15.01 30 9770 14985 29549742
Bladder cancer 28.59 15.01 25 9775 10102 29554625
Epilepsy 27.14 15.01 32 9768 18400 29546327
Hyponatraemia 25.66 15.01 64 9736 67569 29497158
Delirium 25.05 15.01 46 9754 39351 29525376
Dysuria 23.65 15.01 33 9767 22407 29542320
Enterocolitis bacterial 23.59 15.01 7 9793 264 29564463
Product name confusion 21.75 15.01 5 9795 67 29564660
Hypertonic bladder 20.80 15.01 10 9790 1446 29563281
Duodenitis haemorrhagic 20.37 15.01 5 9795 90 29564637
Bladder discomfort 19.60 15.01 5 9795 106 29564621
Pollakiuria 19.52 15.01 26 9774 16890 29547837
Haematuria 19.13 15.01 44 9756 44095 29520632
Somnolence 18.75 15.01 71 9729 93884 29470843
Malaise 18.67 15.01 103 9697 159499 29405228
Pneumonia aspiration 18.62 15.01 39 9761 36698 29528029
Dementia 18.43 15.01 21 9779 11637 29553090
Upper respiratory tract irritation 18.38 15.01 4 9796 41 29564686
Cognitive disorder 18.28 15.01 30 9770 23469 29541258
Body temperature decreased 18.22 15.01 20 9780 10644 29554083
Blood pressure systolic increased 18.09 15.01 25 9775 16820 29547907
Off label use 18.06 15.01 165 9635 300635 29264092
Completed suicide 17.89 15.01 4 9796 90242 29474485
Incontinence 17.46 15.01 14 9786 5018 29559709
Micturition urgency 17.12 15.01 14 9786 5159 29559568
Polyuria 16.54 15.01 16 9784 7346 29557381
Lower urinary tract symptoms 16.33 15.01 5 9795 210 29564517
Foetal heart rate disorder 16.19 15.01 4 9796 74 29564653
On and off phenomenon 15.45 15.01 9 9791 1919 29562808
Cataract 15.33 15.01 27 9773 22351 29542376
Dizziness 15.10 15.01 111 9689 189573 29375154

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dry mouth 154.12 11.35 155 26330 60263 64411984
Fall 134.84 11.35 426 26059 416400 64055847
Urinary retention 123.22 11.35 125 26360 49076 64423171
Multiple sclerosis relapse 98.44 11.35 102 26383 41033 64431214
Confusional state 79.74 11.35 262 26223 260882 64211365
Urinary tract infection 71.26 11.35 233 26252 231363 64240884
Hallucination 69.98 11.35 115 26370 72673 64399574
Urinary incontinence 69.68 11.35 80 26405 36071 64436176
Constipation 64.59 11.35 224 26261 229113 64243134
Fear of eating 61.42 11.35 17 26468 398 64471849
Multiple sclerosis 58.46 11.35 54 26431 18887 64453360
Vision blurred 53.48 11.35 116 26369 90200 64382047
Arteriovenous fistula occlusion 52.43 11.35 16 26469 533 64471714
Residual urine volume increased 52.00 11.35 9 26476 16 64472231
Gait disturbance 46.57 11.35 166 26319 171989 64300258
Toxicity to various agents 45.88 11.35 49 26436 363464 64108783
Blue toe syndrome 43.32 11.35 14 26471 564 64471683
Malaise 41.20 11.35 291 26194 395956 64076291
Hyponatraemia 40.94 11.35 144 26341 148195 64324052
Drug abuse 39.97 11.35 4 26481 132370 64339877
Hallucination, visual 38.24 11.35 52 26433 27782 64444465
Dysuria 35.84 11.35 63 26422 41994 64430253
Renal pain 34.23 11.35 26 26459 6948 64465299
Disorientation 32.23 11.35 71 26414 55757 64416490
Cutaneous T-cell dyscrasia 31.50 11.35 7 26478 63 64472184
Cutaneous lupus erythematosus 30.63 11.35 17 26468 2665 64469582
Dyskinesia 29.75 11.35 56 26429 39332 64432915
Hypertonic bladder 29.33 11.35 18 26467 3400 64468847
Dizziness 29.17 11.35 287 26198 429876 64042371
Dementia 28.84 11.35 39 26446 20727 64451520
Lower urinary tract symptoms 28.64 11.35 8 26477 194 64472053
Balance disorder 28.08 11.35 87 26398 83839 64388408
Cerebellar syndrome 27.53 11.35 20 26465 4996 64467251
Delirium 27.23 11.35 76 26409 69118 64403129
Incontinence 27.18 11.35 29 26456 12052 64460195
Infusion related reaction 25.78 11.35 18 26467 164449 64307798
Gastrointestinal hypomotility 25.48 11.35 13 26472 1720 64470527
Cystitis 25.46 11.35 55 26430 42620 64429627
Nodular rash 25.00 11.35 8 26477 312 64471935
Bladder cancer 24.08 11.35 26 26459 10948 64461299
Treatment failure 23.94 11.35 9 26476 116807 64355440
Duplicate therapy error 23.93 11.35 7 26478 201 64472046
Pollakiuria 22.79 11.35 44 26441 31486 64440761
Poliomyelitis 22.21 11.35 5 26480 48 64472199
Sinus node dysfunction 22.11 11.35 20 26465 6808 64465439
Systemic lupus erythematosus 21.80 11.35 3 26482 77609 64394638
Micturition urgency 21.79 11.35 24 26461 10335 64461912
Synovitis 21.39 11.35 7 26478 99083 64373164
Urosepsis 21.34 11.35 35 26450 22059 64450188
Dyspepsia 21.31 11.35 77 26408 80235 64392012
Bladder discomfort 21.26 11.35 8 26477 508 64471739
Neurogenic bladder 21.17 11.35 15 26470 3604 64468643
Sinus arrest 20.89 11.35 14 26471 3076 64469171
Maternal exposure during pregnancy 20.30 11.35 7 26478 95877 64376370
Renal function test abnormal 19.91 11.35 15 26470 3959 64468288
Epilepsy 19.75 11.35 43 26442 33488 64438759
Upper respiratory tract irritation 18.91 11.35 5 26480 98 64472149
Completed suicide 18.82 11.35 40 26445 224374 64247873
Liver function test abnormal 18.42 11.35 60 26425 59341 64412906
Cognitive disorder 18.32 11.35 57 26428 55030 64417217
Freezing phenomenon 18.21 11.35 10 26475 1536 64470711
Enterocolitis bacterial 17.99 11.35 7 26478 487 64471760
Dry throat 17.75 11.35 17 26468 6215 64466032
Memory impairment 17.75 11.35 76 26409 85606 64386641
Duodenitis haemorrhagic 17.64 11.35 5 26480 128 64472119
Muscular weakness 17.17 11.35 100 26385 127238 64345009
Product name confusion 16.61 11.35 5 26480 159 64472088
Hand deformity 16.33 11.35 3 26482 62768 64409479
Lymphocyte count decreased 16.30 11.35 45 26440 40654 64431593
Pyelonephritis 16.20 11.35 27 26458 17239 64455008
Haematuria 16.06 11.35 58 26427 60413 64411834
On and off phenomenon 16.04 11.35 11 26474 2508 64469739
Oscillopsia 16.04 11.35 5 26480 179 64472068
Cystitis interstitial 15.23 11.35 8 26477 1124 64471123
Therapeutic product effect decreased 15.14 11.35 15 26470 115336 64356911
Thalamus haemorrhage 15.12 11.35 9 26476 1610 64470637
Neutropenia 14.59 11.35 50 26435 239574 64232673
Somnolence 14.31 11.35 137 26348 203508 64268739
Benign renal neoplasm 14.17 11.35 3 26482 21 64472226
Blood viscosity increased 13.89 11.35 5 26480 280 64471967
Pain 13.84 11.35 153 26332 553358 63918889
Labelled drug-drug interaction medication error 13.81 11.35 29 26456 22033 64450214
Acute disseminated encephalomyelitis 13.64 11.35 5 26480 295 64471952
Rheumatoid arthritis 13.18 11.35 30 26455 164264 64307983
Loss of consciousness 13.12 11.35 105 26380 148260 64323987
Oral mucosal eruption 13.04 11.35 6 26479 633 64471614
Bladder disorder 13.00 11.35 16 26469 7751 64464496
Arthralgia 12.81 11.35 118 26367 442142 64030105
Mucosal inflammation 12.52 11.35 5 26480 62579 64409668
Pericarditis 12.50 11.35 5 26480 62511 64409736
Atrial fibrillation 12.47 11.35 116 26369 170973 64301274
Electrocardiogram QT prolonged 12.45 11.35 65 26420 79383 64392864
Stoma site pain 12.44 11.35 7 26478 1126 64471121
Hereditary angioedema with C1 esterase inhibitor deficiency 12.42 11.35 3 26482 40 64472207
Drug hypersensitivity 12.30 11.35 53 26432 237762 64234485
Drug intolerance 12.29 11.35 38 26447 187954 64284293
Lactic acidosis 12.13 11.35 5 26480 61405 64410842
Acute kidney injury 12.13 11.35 255 26230 448985 64023262
Tenoplasty 12.10 11.35 3 26482 45 64472202
Cerebral ventricular rupture 12.01 11.35 5 26480 415 64471832
Genital pain 11.85 11.35 5 26480 429 64471818
Secondary progressive multiple sclerosis 11.84 11.35 7 26478 1236 64471011
Escherichia urinary tract infection 11.53 11.35 19 26466 12018 64460229
Pseudomembranous colitis 11.41 11.35 12 26473 4904 64467343

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD08 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
ATC G04CA53 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000125 Cholinergic Muscarinic Antagonists
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
FDA EPC N0000175700 Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Increased Urinary Frequency indication
Torsades de pointes contraindication 31722008
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Prolonged QT interval contraindication 111975006
Gastrointestinal obstruction contraindication 126765001
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Retention of urine contraindication 267064002
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastrointestinal hypomotility contraindication 421807004
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1MG/ML VESICARE LS ASTELLAS N209529 May 26, 2020 RX SUSPENSION ORAL May 26, 2023 NEW PRODUCT
1MG/ML VESICARE LS ASTELLAS N209529 May 26, 2020 RX SUSPENSION ORAL Nov. 26, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST IC50 6.88 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST IC50 6.24 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M5 GPCR ANTAGONIST Ki 7.20 IUPHAR
Muscarinic acetylcholine receptor M1 GPCR IC50 7.20 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR ANTAGONIST Ki 6.80 IUPHAR
Muscarinic acetylcholine receptor M2 GPCR Ki 6.92 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 8 CHEMBL

External reference:

IDSource
4024390 VUID
N0000022393 NUI
D01269 KEGG_DRUG
242478-38-2 SECONDARY_CAS_RN
4021510 VANDF
4024390 VANDF
C1099677 UMLSCUI
CHEBI:135530 CHEBI
CHEMBL1734 ChEMBL_ID
CHEMBL1200803 ChEMBL_ID
DB01591 DRUGBANK_ID
D000069464 MESH_DESCRIPTOR_UI
154059 PUBCHEM_CID
7483 IUPHAR_LIGAND_ID
8155 INN_ID
A8910SQJ1U UNII
322167 RXNORM
19082 MMSL
256920 MMSL
63797 MMSL
d05413 MMSL
008712 NDDF
008713 NDDF
407030007 SNOMEDCT_US
407031006 SNOMEDCT_US
426324001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3795 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3795 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3796 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3796 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
solifenacin succinate Human Prescription Drug Label 1 27241-037 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
solifenacin succinate Human Prescription Drug Label 1 27241-038 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 29300-328 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 29300-329 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 35561-285 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 35561-286 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 42291-739 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 42291-740 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
Solifenacin Succinate Human Prescription Drug Label 1 46708-192 TABLET, COATED 5 mg ORAL ANDA 27 sections
Solifenacin Succinate Human Prescription Drug Label 1 46708-193 TABLET, COATED 10 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 50228-427 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 50228-428 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 51248-150 TABLET, FILM COATED 5 mg ORAL NDA 26 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 51248-150 TABLET, FILM COATED 5 mg ORAL NDA 26 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 51248-151 TABLET, FILM COATED 10 mg ORAL NDA 26 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 51248-151 TABLET, FILM COATED 10 mg ORAL NDA 26 sections
VESIcareLS HUMAN PRESCRIPTION DRUG LABEL 1 51248-250 SUSPENSION 1 mg ORAL NDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 51407-227 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 51407-228 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 51407-254 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 51407-255 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 51407-471 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 51407-472 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 54868-4705 TABLET, FILM COATED 10 mg ORAL NDA 26 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 54868-5398 TABLET, FILM COATED 5 mg ORAL NDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4702 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections